Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study

Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic HypertensionNovelty and Significance

(2017) Bryan Williams et al.   HYPERTENSION

Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension

(2017) Joseph L. Izzo et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Global Disparities of Hypertension Prevalence and ControlClinical Perspective

(2016) Katherine T. Mills et al.   CIRCULATION

Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension

(2016) Ouppatham Supasyndh et al.   HYPERTENSION RESEARCH

Heart Disease and Stroke Statistics—2016 Update

(2015) Dariush Mozaffarian et al.   CIRCULATION

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction

(2015) Sadayoshi Ito et al.   HYPERTENSION RESEARCH

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015) Mohammad H Forouzanfar et al.   LANCET

Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines

(2015) Stefano Omboni et al.   Clinical Interventions in Aging

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

(2014) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

(2014) Kazuomi Kario et al.   HYPERTENSION

Prognostic Value of Blood Pressure Variability and Average Blood Pressure Levels in Patients With Hypertension and Diabetes

(2013) G. Parati et al.   DIABETES CARE

Ambulatory Blood Pressure Measurement

(2013) Eoin O’Brien et al.   HYPERTENSION

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

(2013) Paul A. James et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin–Angiotensin System Inhibitors

(2012) Harikrishna Makani et al.   AMERICAN JOURNAL OF CARDIOLOGY

Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System

(2012) Sengwee Toh et al.   ARCHIVES OF INTERNAL MEDICINE

Optimizing blood pressure control in hypertension: The need to use ABPM

(2012) Roland E. Schmieder et al.   BLOOD PRESSURE

Rationale for Triple-Combination Therapy for Management of High Blood Pressure

(2010) Alan H. Gradman   Journal of Clinical Hypertension

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Association of Hypertension Treatment and Control With All-Cause and Cardiovascular Disease Mortality Among US Adults With Hypertension

(2009) Q. Gu et al.   AMERICAN JOURNAL OF HYPERTENSION

Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease

(2009) Stanley S. Franklin et al.   CIRCULATION

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

(2007) R M Fryer et al.   BRITISH JOURNAL OF PHARMACOLOGY